DROSPIRENONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H30O3
Molecular Weight	366.4932
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C5=CC(=O)CC[C@]35C)[C@@H]1[C@@H]6C[C@@H]6[C@@]27CCC(=O)O7

InChI

InChIKey=METQSPRSQINEEU-HXCATZOESA-N

InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C24H30O3
Molecular Weight	366.4932
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021098s023lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7625729 | https://www.ncbi.nlm.nih.gov/pubmed/23530659 | https://www.ncbi.nlm.nih.gov/pubmed/7107766 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf

Drospirenone (INN, USAN), also known as 1,2-dihydrospirorenone, is a steroidal progestin of the spirolactone group. Drospirenone binds strongly to the progesterone receptor (PR) and mineralocorticoid receptor (MR), with lower affinity, to the androgen receptor (AR), and very low affinity for the glucocorticoid receptor (GR). Drospirenone is an ingredient in some birth control pills and hormone replacement therapy. In combination with ethinylestradiol it is used as contraception, and for women who want contraception it is also approved by the U.S. Food and Drug Administration (FDA) to treat vasomotor symptoms due to menopause.It is sold as a combined oral contraceptive under the brand names Yasmin (US, EU, Latin America), Jasmine (France), Yarina (Russia) in a dosage containing drospirenone 3 mg/ethinylestradiol 30 µg. In the United States, Bayer Schering released a pill based on Yasmin with the B vitamin folate (B9), which is marketed under the names Safyral and Beyaz.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mineralocorticoid receptor 53 Target ID: CHEMBL1994 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729	Antagonist 2849
Progesterone receptor 61 Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729	Agonist 2752
Androgen Receptor 169 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729	Antagonist 2849

Conditions

Condition	Modality	Highest Phase	Product
Pregnancy 65 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021098s023lbl.pdf	Primary	Approved 8583	YASMIN Approved Use INDICATIONS AND USAGE. Yasmin is an estrogen/progestin COC indicated for use by women to prevent pregnancy Launch Date 2001
Vasomotor symptoms due to menopause 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf	Primary	Approved 8583	Angeliq Approved Use Indications and Usage ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Launch Date 2005
Vulvar and vaginal atrophy symptoms due to menopause 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf	Primary	Approved 8583	Angeliq Approved Use Indications and Usage ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Launch Date 2005

C_max

Value	Dose	Analyte	Population
9.85 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
33.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
62.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
27 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
41 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf	4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
140 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
506 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
1007 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
25.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
26.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
30 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
30 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf	4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
4% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf	4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered:		DROSPIRENONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	healthy, 17 - 40 years Health Status: healthy Age Group: 17 - 40 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	Disc. AE: Premenstrual syndrome, Migraine headache... Other AEs: Premenstrual syndrome, Migraine headache... AEs leading to discontinuation/dose reduction: Premenstrual syndrome (6.7%) Migraine headache (1.5%) Other AEs: Premenstrual syndrome (13.2%) Migraine headache (10.7%) Breast discomfort (8.3%) Nausea and vomiting (4.5%) Abdominal discomfort (2.3%) Mood change (2.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/	healthy, mean 25.1 years Health Status: healthy Age Group: mean 25.1 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/	Disc. AE: Weight gain, Headache... AEs leading to discontinuation/dose reduction: Weight gain (> 0.45) Headache (> 0.45) Depression (> 0.45) Menorrhagia (> 0.45) Skin disorder (> 0.45) Emotional lability (> 0.45) Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/

AEs

AE	Significance	Dose	Population
Migraine headache	1.5% Disc. AE	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	healthy, 17 - 40 years Health Status: healthy Age Group: 17 - 40 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf
Migraine headache	10.7%	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	healthy, 17 - 40 years Health Status: healthy Age Group: 17 - 40 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf
Premenstrual syndrome	13.2%	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	healthy, 17 - 40 years Health Status: healthy Age Group: 17 - 40 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf
Abdominal discomfort	2.3%	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	healthy, 17 - 40 years Health Status: healthy Age Group: 17 - 40 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf
Mood change	2.3%	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	healthy, 17 - 40 years Health Status: healthy Age Group: 17 - 40 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf
Nausea and vomiting	4.5%	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	healthy, 17 - 40 years Health Status: healthy Age Group: 17 - 40 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf
Premenstrual syndrome	6.7% Disc. AE	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	healthy, 17 - 40 years Health Status: healthy Age Group: 17 - 40 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf
Breast discomfort	8.3%	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	healthy, 17 - 40 years Health Status: healthy Age Group: 17 - 40 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf
Depression	> 0.45 Disc. AE	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/	healthy, mean 25.1 years Health Status: healthy Age Group: mean 25.1 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/
Emotional lability	> 0.45 Disc. AE	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/	healthy, mean 25.1 years Health Status: healthy Age Group: mean 25.1 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/
Headache	> 0.45 Disc. AE	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/	healthy, mean 25.1 years Health Status: healthy Age Group: mean 25.1 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/
Menorrhagia	> 0.45 Disc. AE	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/	healthy, mean 25.1 years Health Status: healthy Age Group: mean 25.1 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/
Skin disorder	> 0.45 Disc. AE	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/	healthy, mean 25.1 years Health Status: healthy Age Group: mean 25.1 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/
Weight gain	> 0.45 Disc. AE	3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/	healthy, mean 25.1 years Health Status: healthy Age Group: mean 25.1 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/16542051/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057 CYP1A1 132

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0	minimum
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0	minimum
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021098Orig1s022.pdf#page=24 Page: 25.0	moderate [IC50 31200 uM]	no (co-administration study) Comment: "IC50 units given are ""mM""; no significant effect of DRSP on the systemic clearance of the CYP3A4 product omeprazole sulfone was found" Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021098Orig1s022.pdf#page=24 Page: 25.0
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0	moderate [IC50 36500 uM]
CYP1A1 272	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0	yes [IC50 14500 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021098Orig1s022.pdf#page=24 Page: 25.0	yes [IC50 3390 uM]	no (co-administration study) Comment: "IC50 units given are ""mM""; daily oral administration of 3 mg DRSP for 14 days did not affect the oral clearance of omeprazole (40 mg, single oral dose) and the CYP2C19 product 5-hydroxy omeprazole" Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021098Orig1s022.pdf#page=24 Page: 25.0

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0	yes		no (co-administration study) Comment: simvastatin is not expected to affect DRSP's metabolism; When tested with midazolam, PK parameters of midazolam were similar regardless whether it was dosed with DSRP or with placebo. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:50838	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50838
ChemicalBook	CB8695608	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8695608
eMolecules	10229968	https://www.emolecules.com/cgi-bin/more?vid=10229968
eMolecules	29780522	https://www.emolecules.com/cgi-bin/more?vid=29780522
eMolecules	31588151	https://www.emolecules.com/cgi-bin/more?vid=31588151
MolPort	MolPort-003-847-034	https://www.molport.com/shop/molecule-link/MolPort-003-847-034
Selleck Chemicals	Drospirenone	http://www.selleckchem.com/products/Drospirenone.html
ZINC	ZINC000003927200	http://zinc15.docking.org/substances/ZINC000003927200

PubMed

Title	Date	PubMed
Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio.	2006-02	16239318
The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days.	2006-01	16371292
Treating acne with oral contraceptives: use of lower doses.	2006-01	16371290
Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women.	2005-12	16313478
Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.	2005-12	16307962
Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells.	2005-12	16157482
New progestagens for contraceptive use.	2005-11-18	16291771
Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.	2005-11-10	16278615
Effects of drospirenone/estrogen combinations on bone metabolism.	2005-10	16203654
Added benefits of drospirenone for compliance.	2005-10	16203653
Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.	2005-10	16203652
Importance of controlling blood pressure.	2005-10	16203651
Pharmacology of different progestogens: the special case of drospirenone.	2005-10	16203650
Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms.	2005-10	16203649
Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.	2005-09-27	16186434
Gateways to clinical trials.	2005-09	16258596
Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.	2005-09	16135578
Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive.	2005-07	15964287
Systemic sclerosis following oral contraception.	2005-06	15940568
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.	2005-06	15925739
Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.	2005-06	15914128
Different oral contraceptives and voice quality--an observational study.	2005-05	15854635
Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat.	2005-03	15857755
Drospirenone and PCOS.	2005-01	15720866
A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.	2005-01	15639064
Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density.	2005-01	15625142
Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").	2005-01	15531905
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.	2005-01	15483105
New contraception options.	2004-12-14	15586908
Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate.	2004-11	15550051
The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy.	2004-11	15542048
Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women.	2004-10	15451333
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.	2004-09	15356085
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.	2004-09	15325887
Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.	2004-08	15379365
Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.	2004-08	15229206
An observational study of Yasmin in the management of women with polycystic ovary syndrome.	2004-07	15222920
Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens.	2004-06	15497908
Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.	2004-06	15181063
Ethinyl estradiol/drospirenone (Yasmin): a newer oral contraceptive.	2004-05-15	15168965
Pharmacological profile of progestins.	2004-04-15	15063480
Enhancing oral contraceptive success: the potential of new formulations.	2004-04	15105795
Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.	2004-04	15070917
Drospirenone, a progestogen with antimineralocorticoid properties: a short review.	2004-03-31	15134826
Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis.	2004-03	15259289
[Medication of the month. Angeliq: new hormonal therapy of menopause, with antialdosterone and antiandrogenic properties].	2004-03	15139405
New progestogens: a review of their effects in perimenopausal and postmenopausal women.	2004	15493951
Safety of a new oral contraceptive containing drospirenone.	2004	15471507
Progestogens in combined oral contraceptives for contraception.	2004	15266546
Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.	2003	15871554

Patents

Sample Use Guides

In Vivo Use Guide

To prevent pregnancy: One tablet (containing 3 mg drospirenone and 0.03 mg ethinyl estradiol) daily by mouth at the same time every day. To prevent symptoms due to menopause. one tablet (0.25 mg drospirenone/0.5 mg ethinyl estradiol) taken by mouth once daily

Route of Administration: Oral

In Vitro Use Guide

Activity of drospirenone was investigated by transiently transfecting the human MR (pRShMR) and pMMTV-CAT into COS 1 cells. Cells were treated with 10 nmol/l aldosterone and, in addition, with increasing amounts of the drospirenone (1nM – 1 mkM). After 48 hrs cells were harvested and duplicate dishes were assayed for activity

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:57:05 GMT 2025` Edited by `admin` on `Wed Apr 02 09:57:05 GMT 2025`
Record UNII	N295J34A25
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANGELIQ COMPONENT DROSPIRENONE

Preferred Name

English

DROSPIRENONE

Official Name

English

DROSPIRENONE [USP MONOGRAPH]

Common Name

English

NSC-760103

Code

English

DROSPIRENONE [MART.]

Common Name

English

(6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6A,7,8,9,10,11,12,13,14,15,15A,16-HEXADECAHYDRO-10,13-DIMETHYLSPIRO-(17H-DICYCLOPROPA(6,7:15,16)CYCLOPENTA(A)PHENANTHRENE-17,2'(5'H)-FURAN)-3,5'(2H)-DIONE

Common Name

English

DROSPIRENONE [MI]

Common Name

English

SLYND

Brand Name

English

drospirenone [INN]

Common Name

English

ZK-30595

Code

English

DROSPIRENONE [USP-RS]

Common Name

English

YASMIN COMPONENT DROSPIRENONE

Common Name

English

YAZ COMPONENT DROSPIRENONE

Common Name

English

BEYAZ COMPONENT DROSPIRENONE

Common Name

English

DROSPIRENONE [JAN]

Common Name

English

DROSPIRENONE [EP MONOGRAPH]

Common Name

English

SAFYRAL COMPONENT DROSPIRENONE

Common Name

English

DROSPIRENONE [USAN]

Common Name

English

DROSPIRENONE [VANDF]

Common Name

English

17-Hydroxy-6?,7?:15?,16?-dimethylene-3-oxo-17?-pregn-4-ene-21-carboxylic acid, ?-lactone

Common Name

English

ZK 30595

Code

English

DROSPIRENONE [ORANGE BOOK]

Common Name

English

Drospirenone [WHO-DD]

Common Name

English

NEXTSTELLIS COMPONENT DROSPIRENONE

Brand Name

English

DRSP

Common Name

English

Classification Tree Code System Code

WHO-ATC

G03AC10